Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hormone Secretion01:19

Regulation of Hormone Secretion

6.0K
Regulation of hormone secretion is a finely tuned orchestration driven by various types of stimuli, encompassing neural, humoral, and hormonal signals. Environmental cues instigate neural stimuli, where action potentials traverse nerve fibers to reach their designated targets. An illustrative scenario is the body's response to stress, wherein the sympathetic nervous system releases epinephrine from the adrenal glands, inducing the well-known 'fight or flight' reaction.
Humoral...
6.0K
Hormonal Regulation01:40

Hormonal Regulation

47.7K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
47.7K
Overview of Secretory Vesicles01:33

Overview of Secretory Vesicles

9.3K
Secretory vesicles, also known as dense core vesicles (DCVs), are membrane-bound vesicles that transport secretory proteins, such as hormones or neurotransmitters. Regulated secretory vesicles transport proteins from the trans-Golgi network to the exterior of the cell. Proteins present in regulated secretory vesicles are required to be rapidly exocytosed in large amounts upon a specific stimulus.
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...
9.3K
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

6.3K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.3K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.1K
Feedback Inhibition00:46

Feedback Inhibition

56.8K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
56.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.

Nature communications·2026
Same author

A cell-intrinsic glucocorticoid biosynthesis and sensing circuit maintains a homeostatic Th17 cell state.

Immunity·2026
Same author

Interleukin 23 promotes a pro-inflammatory Th17 cell state by stabilizing RORγt and suppressing glucocorticoid receptor activity.

Immunity·2026
Same author

Cell-type- and state-resolved transcriptomics uncovers distinct T cell and monocyte dysregulation in multiple sclerosis.

Cell reports·2026
Same author

An adaptive cellular source of IL-17A and IL-17F is critical for the induction of experimental autoimmune encephalomyelitis.

Science immunology·2026
Same author

The dual role of TOX in regulating T<sub>H</sub>1 and CD8<sup>+</sup> T cell fate.

Nature immunology·2026

Related Experiment Video

Updated: Jan 9, 2026

Regulation of Hormone Secretion
01:19

Regulation of Hormone Secretion

6.0K

IL-17 Blockade in Psoriasis.

Patrick R Burkett1, Vijay K Kuchroo2

  • 1Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham & Women's Hospital, Boston, MA 02115, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham & Women's Hospital, Boston, MA 02115, USA.

Cell
|December 17, 2016
PubMed
Summary

Interleukin-17A (IL-17A) drives autoimmune inflammation. Monoclonal antibodies secukinumab and ixekizumab targeting IL-17A are approved for psoriasis and related conditions.

More Related Videos

Hormonal Regulation of Digestion
01:40

Hormonal Regulation of Digestion

47.7K
Overview of Secretory Vesicles
01:33

Overview of Secretory Vesicles

9.3K

Related Experiment Videos

Last Updated: Jan 9, 2026

Regulation of Hormone Secretion
01:19

Regulation of Hormone Secretion

6.0K
Hormonal Regulation of Digestion
01:40

Hormonal Regulation of Digestion

47.7K
Overview of Secretory Vesicles
01:33

Overview of Secretory Vesicles

9.3K

Area of Science:

  • Immunology
  • Rheumatology
  • Dermatology

Background:

  • Interleukin-17A (IL-17A) is a key cytokine mediating autoimmune tissue inflammation.
  • IL-17A directly induces inflammation and synergizes with other inflammatory cytokines.

Purpose of the Study:

  • To review the therapeutic applications of IL-17A inhibitors.
  • To highlight the efficacy of secukinumab and ixekizumab in treating inflammatory conditions.

Main Methods:

  • Review of clinical trial data and regulatory approvals.
  • Analysis of the mechanism of action for IL-17A monoclonal antibodies.

Main Results:

  • Secukinumab and ixekizumab, as monoclonal antibodies (mAb), effectively inhibit IL-17A.
  • Both agents are approved for the treatment of psoriasis.
  • Secukinumab is also approved for psoriatic arthritis and ankylosing spondylitis.

Conclusions:

  • Targeting IL-17A with monoclonal antibodies represents a significant advancement in treating autoimmune and inflammatory diseases.
  • Secukinumab and ixekizumab offer effective therapeutic options for patients with psoriasis and spondyloarthropathies.